Paget's Sarcoma (Sarcomatous Transformation of Paget Disease)

Paget sarcoma is a high-grade bone sarcoma arising in a bone affected by Paget disease, and osteosarcoma is its dominant subtype. It is uncommon, but it ties together two of the most heavily examined musculoskeletal topics, Paget disease of bone and the primary malignant bone tumours. Know the risk, the dominant histology and the presentation pattern, and be able to separate Paget sarcoma from a giant cell tumour arising in Paget, which is a separate, often benign entity.

Risk. In modern cohorts fewer than 1% of patients with Paget disease develop sarcomatous transformation. The older literature quoted 5-10%; the true risk is lower, but the absolute number of cases is high because Paget affects 1-2% of adults over 55 in European populations. The sarcoma almost always arises in polyostotic or long-standing Paget: polyostotic disease carries a higher risk than monostotic, and the longer the disease has been active and the more bones involved, the higher the cumulative risk.

Who. The median age is 60-70 years, decades older than in primary osteosarcoma, and there is a slight male predominance.

Where. Pelvic and long-bone sites dominate, above all the pelvis, proximal femur and proximal humerus. In Huvos's series the pelvis accounted for 34%, the humerus 22%, the femur 19% and the craniofacial bones 14%.

The spine is spared. Paget disease has a strong predilection for the axial skeleton and spine, yet pagetic sarcoma conspicuously spares the spine. A vertebra riddled with Paget disease very rarely becomes the site of the sarcoma, while the pelvis and humerus are over-represented relative to their share of pagetic bone, so the distribution of the sarcoma does not simply mirror that of the disease. Nobody has explained this convincingly, and it is a good discriminator to be able to state.

The cost. Five-year overall survival is 5-25%, markedly worse than primary osteosarcoma in adolescents. Lung metastases are present at diagnosis in 10-25%, and most patients need a major resection, often pelvic or proximal femoral, or an amputation.

The disease underneath. Paget disease is a disorder of dysregulated bone remodelling driven by abnormal osteoclasts. They contain characteristic nuclear and cytoplasmic inclusions, paramyxovirus-like on electron microscopy and possibly viral in origin, and the disease is associated with somatic mutations in the SQSTM1/p62 gene. The relentless remodelling cycle (lytic, mixed, sclerotic) creates a high bone-turnover state with disordered matrix.

The step to sarcoma. Over years, genomic instability accumulates and a clonal high-grade sarcoma emerges, most often osteosarcoma. The model is stepwise:

1. SQSTM1/p62 mutation drives abnormal osteoclast signalling through the NF-kB pathway
2. A chronic high-turnover state, with disordered lamellar bone
3. Decades of cellular stress, with p53 mutation and chromosomal aneuploidy
4. A clonal high-grade sarcoma, its osteoid matrix produced by malignant cells

View larger

Paget sarcoma is classified three ways: by histology, which drives chemotherapy sensitivity; by site, which governs resectability; and by local extent. Osteosarcoma dominates the histology, and chondrosarcoma is relatively chemo-resistant.

The history. The background is known Paget disease, often polyostotic and present for many years. The complaint is a change in the pain at a known Paget site: new in onset, escalating, or waking the patient at night. Weight loss and fatigue suggest a high-grade malignancy. Ask about function (a limp, reduced range, inability to weight-bear) and about a pathological fracture after minimal trauma.

The examination. Look for deformity of the Paget bone and for new swelling or asymmetry. Palpate for a hard, often fixed mass with warm overlying skin, and test movement for restricted range and pain at end-range. Rule out nerve or vessel compromise, especially with pelvic lesions; lymphadenopathy is rare, and there may be chest signs if there are lung metastases.

The red flags in a Paget bone are new or worsening pain, a new palpable mass and a pathological fracture. Constant or night pain is malignant until proven otherwise. ALP may already be elevated by the Paget disease, so a rise above the patient's own stable baseline is suspicious but not specific.

The differential. Not every new lesion in a Paget bone is a sarcoma, and the imaging clue and the key test separate the alternatives.

Radiographs first. AP and lateral views of the painful segment, including the whole bone and the joint above and below. Paget disease alone gives a coarsened trabecular pattern, cortical thickening and bone enlargement; sarcoma superimposes a destructive pattern on the pagetoid bone, with cortical lysis, periosteal reaction, a soft-tissue mass or a pathological fracture. Compare with prior films: any change in the Paget appearance is suspicious, and any new finding within a Paget bone is malignant until proven otherwise.

View larger

MRI of the whole bone is indicated in every suspected Paget sarcoma and is the best modality for local staging. It defines the intraosseous and extraosseous extent: marrow oedema beyond that expected from Paget, a soft-tissue mass and neurovascular involvement. Sequences are T1, STIR and post-contrast T1 fat-sat, and the study includes the whole bone to catch skip lesions.

CT of the lesion gives better cortical detail than MRI, showing cortical breakthrough, fracture lines and matrix mineralisation. It is the surgical planning study, used for the biopsy trajectory and for endoprosthetic sizing.

Distant staging. CT chest, because the lungs are the first site of metastasis in osteosarcoma, and a bone scan or PET to identify other Paget-involved bones and any skip lesions. Both provide a baseline for post-treatment surveillance.

Biopsy comes last. Full imaging comes first, to identify the most representative target and to plan the tract; never incise or biopsy first. The biopsy is a core needle biopsy by a musculoskeletal radiologist or surgeon from the tumour centre:

• At least 3-4 cores from the solid, viable part of the tumour
• Through a planned tract along the future resection corridor, which will be excised at definitive surgery
• Without contaminating uninvolved compartments or letting haematoma drain away from the resection bed

The principle. Wide surgical resection, limb-sparing when oncologically safe, plus multi-agent chemotherapy for the osteosarcoma subtype. Radiotherapy is reserved for unresectable or margin-positive disease, and bisphosphonates or denosumab control ongoing Paget activity. Each pathway below starts with the sarcoma MDT.

Why outcomes are so poor. The patients are older, and comorbidities limit chemotherapy dose-intensity. The tumour is often axial or pelvic, which limits resectability; it is high grade at presentation in the majority, its p53-driven biology is often chemo-resistant, and lung metastases are common at diagnosis. Diagnosis is delayed when symptoms are wrongly attributed to Paget pain.

Stage and resectability dominate. In Longhi's Rizzoli series of patients over 65, stage, tumour volume and surgery were significant prognostic factors on multivariate analysis and Paget disease itself was not. With only 13 Paget sarcomas that null cannot exclude a real effect of pagetic biology, but it points the blame at late presentation and unresectable axial bulk.

Prognostic factors. The outlook is better with an appendicular site, a small tumour, no pathological fracture, R0 margins and a patient able to tolerate full-dose chemotherapy. It is worse with:

• An axial or pelvic site
• Large size, greater than 8 cm
• Pathological fracture at presentation
• Positive margins; an intralesional margin makes local recurrence inevitable
• Lung metastases at diagnosis
• Poor performance status